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A Commentary on
Probiotic and technological properties of Lactobacillus spp. strains from the human stomach
in the search for potential candidates against gastric microbial dysbiosis
by Delgado, S., Leite, A. M. O., Ruas-Madiedo, P., and Mayo, B. (2014). Front. Microbiol. 5:766. doi:
10.3389/fmicb.2014.00766
Helicobacter pylori, a curved-shaped, flagellated, microaerophilic, gram-negative bacillus is
naturally colonized bacteria in humans. This bacterium can be found in 25–50% of the population
in developed countries and in 70–90% in developing countries, probably, due to the poor hygiene
(Go, 2002). New epidemiological studies revealed that the prevalence of H. pylori is declining.
However, H. pylori-infected population develops various diseases including peptic ulcer, chronic
gastritis, and gastric mucosa-associated lymphoid tissue (MALT) lymphoma (Ruggiero, 2014).
It is the only bacterium that has been linked to the gastric cancer and ulcer disease, and thus
associated with significant morbidity and mortality worldwide. Moreover, till now there is no
universally effective therapeutic regimen and vaccine are available for the treatment of H. pylori
associated diseases. Although triple therapy (combining acid suppression with clarithromycin,
amoxicillin, or nitroimidazolic compounds) and antibiotics are being used against H. pylori
infection, prolongation of these therapeutic agents is declining worldwide because of their side
effects (such as vomiting, diarrhea, nausea, constipation, headache, etc.) (Yuan et al., 2013) and
prevalence of antimicrobial resistance.H. pylori eradication treatments are still remain a challenge.
Extensive research on H. pylori and associated diseases concluded that probiotics can be used
as an alternative or complementary therapy for the management of H. pylori infection (Emara
et al., 2014), since it does not cause side effects as triple therapy. Probiotics have potential
to maintain the disturbed gastroenterological conditions and also beneficial for the patients of
inflammatory bowel disease, ulcerative colitis, Crohn’s disease, antibiotic-, and rotavirus-associated
diarrhea, adenocarcinoma, colorectal cancer, etc. (Goossens et al., 2003). An improvement of H.
pylori associated gastric inflammation by the use of probiotics could be contributed by various
mechanisms (Emara et al., 2014). Accumulated evidences suggested that H. pylori could be
eradicated from the stomach by selective bacterial–bacterial cell interaction. Lactobacillus reuteri
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was identified as a highly specific binding antagonist to H.
pylori among Lactobacillus species. L. reuteri DSM17648 strain
co-aggregates with different H. pylori strains and serotypes.
However, it does not affect other intestinal and commensal oral
bacteria (Holz et al., 2015).
How L. reuteri acts against H. pylori is not completely
uncovered. However, it is reported that L. reuteri produces
a compound called reuterin, which work as an antimicrobial
agent. Other than reuterin, L. reuteri also produces some potent
antimicrobial compounds, such as reutericin 6 and reutericyclin,
but these have no effects on Gram-negative bacteria (Ganzle,
2004). L. reuteri also inhibits the binding of H. pylori to the
putative glycolipid receptors. Mukai et al. (2002) examined the
binding competition of L. reuteri strains, (JCM1081 and TM105)
and H. pylori to gangliotetraosylceramide (asialo-GM1) and
sulfatide. It was identified as a possible sulfatide-binding protein
of the L. reuteri strain.
L. reuteri helps to improve the eradication rate of H. pylori
induced by triple therapy (Table 1). In a recent clinical trial, it
was observed that triple therapy supplemented with L. reuteri
increased the eradication rate of H. pylori by 8.6%, as well as
reduced the side effects and improve the GSRS (Gastrointestinal
Symptom Rating Scale) score (Emara et al., 2014). A new
probiotic having two strains of L. reuteri (DSM 17938 and
ATCC PTA 6475) were also studied for the inhibitory effect
TABLE 1 | Selected clinical trials using Lactobacillus reuteri for H. pylori eradication treatment.
Treatment Probiotic(s) Eradication rate Probiotic efficacy References
Triple therapy, Omeprazole 20 mg,
amoxicillin 1 g, clarithromycin 500
mg, 14 d
L. reuteri ATCC PTA 6475, L. reuteri
DSM 17938, 14 d during therapy +
further 14 d, Control
74.3% (26/35)
65.7% (23/35)
Significantly increase of eradication rate
with improved GSRS score and
reduction of side effects (taste disorder,
diarrhea)
Emara et al., 2014
Three-phase study; pre-eradication
(1–28 d), eradication (29–35 d),
follow-up (36–96 d), Triple therapy
L. reuteri ATCC PTA 6475, L. reuteri
DSM 17938 Control
75% (37/50)
65.9% (33/50)
Significantly increase of eradication rate
but no difference in GSRS score
Francavilla et al.,
2014
Pantoprazole 20 mg, 8 weeks L. reuteri, 8 weeks 14.2% (3/21) Good tolerability with no side effects Dore et al., 2014
Levofloxacin 500 mg, esomeprazole
20 mg, amoxicillin 1 g, 7 d
L. reuteri, during therapy + further 7
d Control
80% (36/45)
62.2% (28/45)
Significantly increase of eradication rates
and reduction of side effects (Nausea,
diarrhea)
Ojetti et al., 2012
Omeprazole 1mg/kg, amoxicillin
50mg/kg, clarithromycin 15mg/kg,
7 d
L. plantarum, L. reuteri, L. casei
subsp. rhamnosus, B. infantis, and
B. longum, L. acidophilus, L.
salivarius, S. thermophilus, L.
sporogenes, during therapy Control
82.2% (30/34)
76.4% (26/34)
Non-significant increase of eradication
rates; significant reduction of side effects
(epigastric pain, nausea, vomiting,
diarrhea)
Tolone et al., 2012
Pantoprazole 20 mg, amoxicillin 1
g, clarithromycin 500 mg, Triple
therapy, 7 d Sequential regimen,
10 d
L. reuteri ATCC55730, during
therapy + further 7 or 10 d
63% (52/83)
88% (73/83)
Significantly higher eradication rate and
reduction of side effects in Sequential
regimen
Efrati et al., 2012
Sequential therapy (Details not
describe)
L. reuteri ATCC55730, 8 weeks
Control
33.8 ± 15% (33)
35.8 ± 15.5% (33)
Significant decrease in Gastrointestinal
Symptom
Francavilla et al.,
2008
Triple therapy (Details not describe) L. reuteri, 7 d Control 63% 53% Lowest incidence of side-effects Scaccianoce
et al., 2008
No drug L. reuteri SD2112, 8 weeks 69.7 ± 4% (33) Significant reduction of 13C-UBT Imase et al., 2007
Omeprazole 1mg/kg, amoxicillin
50mg/kg, clarithromycin 15mg/kg,
Sequential therapy, 10 d
L. reuteri ATCC55730 (SD2112)
Control
85% (17/20)
80% (16/20)
Significant reduction of GSRS score Lionetti et al.,
2006
GSRS, Gastro intestinal Symptom Rating Scale; 13C-UBT, 13C Urea Breath Test.
of H. pylori growth, gastritis and prevention of antibiotic-
associated side effects, when administered with triple therapy.
L. reuteri combination increased the eradication rate by 9.1%
(Francavilla et al., 2014). Sequential therapy with L. reuteri
supplementation was also reported in the eradication treatment
of H. pylori and the intensity of antibiotic-associated side
effects (Efrati et al., 2012). H. pylori infection was also defined
as positive gastric histopathology 13C urea breath test (13C-
UBT). Dore et al. (2014) have done an open label single
center study, where they found a significant reduction in urease
activity with a difference of mean of 38.8 vs. 25.4 assessed
before and 4–6 weeks post therapy. In another study, L.
reuteri DSMZ17648 was also reported to co-aggregates with
H. pylori in vitro and was shown to reduce 13C-UBT in vivo
(Mehling and Busjahn, 2013).
Antibiotic-associated gastrointestinal side effects are
major drawbacks of all H. pylori therapies. One of them is
levofloxacin-based second-line therapy. The efficacy of L. reuteri
supplementation during a second-line levofloxacin triple therapy
for H. pylori eradication was reported by Ojetti et al. (2012).
In this study, The H. pylori eradication rate was significantly
increased (18%) and incidence of nausea and diarrhea was
significantly lowered due to the L. reuteri supplementation. The
therapeutic role of L. reuteri was also compared with a high
concentration of probiotics for H. pylori eradication, where
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the incidence of side effects was lowest in 7-day therapy plus
L. reuteri (6%) treated group (Scaccianoce et al., 2008). These
studies show that L. reuteri can be used as a complementary
therapy for H. pylori infection. L. reuteri may compete directly
with H. pylori, possibly by interference with adherence or by the
production of antimicrobial molecules.
In a recent “Frontiers in Microbiology” paper by Delgado
et al. (2014), authors isolated 10 strains of different Lactobacillus
species from the gastric biopsies and stomach juice samples of
healthy humans. These all strains were tested for their functional
properties, like bile tolerance, acid resistance, adhesion to
epithelial gastric cells, production of antimicrobial compounds,
antioxidative activity, antibiotic resistance, carbohydrate
fermentation, glycosidic activities, and inhibition of H. pylori. In
vitro, two gastric strains (particularly LR32 and LR34) showed
good survival under gastrointestinal conditions, along with
strong anti-Helicobacter and antioxidative activities. Thus, these
strains can be considered as promising probiotic candidates.
The data presented have important implications for different
disciplines including gastroenterology, microbial ecology,
colorectal cancer, nutrition and health. Thus, based on these
findings following intriguing questions can be raised: (1) To
what extent L. reuteri is helpful for the prevention of H. pylori-
induced colorectal cancer? (2) If it is available in our stomach
or gut, how L. reuteri population can be increased inside the
gut? (3) What could be the other potential probiotics and
nutraceuticals, which can synergize the growth of L. reuteri in
the gut?
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